Vyleesi (bremelanotide injection) is the first and only FDA-approved as-needed treatment for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). It was approved by the FDA on June 21, 2019. Do not use if you have: high blood pressure that is not controlled (uncontrolled hypertension) known heart (cardiovascular) disease See clinical trials info.